Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398876 | 0.85 | KDM4E (0.41) | HRH1CYP3A4 | |
| SCHEMBL2398439 | 0.84 | HTR2A (0.42) | SLC6A4HTR2AHRH1HTR1DHTR1B | |
| SCHEMBL2397906 | 0.83 | DRD3 (0.37) | SLC6A4HTR2AHRH1HTR1DHTR1B | |
| SCHEMBL2398470 | 0.83 | LMNA (0.40) | SLC6A4HTR2AHRH1SLC6A2CYP3A4 | |
| SCHEMBL2398440 | 0.80 | SLC6A4 (0.39) | SLC6A4HTR2AHRH1HTR1DHTR1B | |
| SCHEMBL2398467 | 0.71 | ALDH1A1 (0.37) | SLC6A4SLC6A2CYP3A4SLC6A3NOS2 | |
| SCHEMBL2398937 | 0.70 | KDM4E (0.38) | HTR2AHRH1SIGMAR1CYP3A4 | |
| SCHEMBL2397027 | 0.70 | HTT (0.35) | PDPK1 | |
| SCHEMBL2407513 | 0.68 | CYP1A2 (0.53) | SLC6A4HTR2AHRH1CYP3A4CYP2D6 | |
| SCHEMBL2399694 | 0.68 | KDM4E (0.41) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | claimed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | claimed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | claimed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | claimed |
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | SLC6A4 4662/4885HTR2A 4731/4885HRH1 3179/4885 |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | SLC6A4 1824/4885HTR2A 3362/4885HRH1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.